利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.015 秒)

    Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
    1.
    发明申请
    Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle 审中-公开
    含药纳米颗粒，其制备方法和从该纳米颗粒肠胃外给药的制剂

    公开(公告)号：US20070077286A1

    公开(公告)日：2007-04-05

    申请号：US10596828

    申请日：2004-10-12

    申请人： Tsutomu Ishihara ,  Yutaka Mizushima ,  Jun Suzuki ,  Junzou Sekine ,  Yoko Yamaguchi ,  Rie Igarashi

    发明人： Tsutomu Ishihara ,  Yutaka Mizushima ,  Jun Suzuki ,  Junzou Sekine ,  Yoko Yamaguchi ,  Rie Igarashi

    IPC分类号： A61K9/70 ,  A61K9/14

    CPC分类号： A61K9/0024 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5192 ,  A61K31/07 ,  A61K31/122 ,  A61K31/198

    摘要： To provide an external preparation or injectable preparation that exerts the effect of enabling transdermal or transmucosal in viva absorption of fat-soluble drugs and water-soluble drugs not having been satisfactorily attained hitherto and that contains a highly absorbable fat-soluble/water-soluble drug, the injectable preparation especially aiming at sustained-release and target effects. In particular, drug-containing nanoparticles (secondary nanoparticles) are provided by causing primary nanoparticles containing a fat-soluble drug or fat-solubilized water-soluble drug to act with a bivalent or trivalent metal salt. Further, drug-containing nanoparticles (tertiary nanoparticles) are provided by first causing primary nanoparticles containing a fat-soluble drug or fat-solubilized water-soluble drug to act with a bivalent or trivalent metal salt to thereby obtain secondary nanoparticles and thereafter causing a monovalent to trivalent basic salt to act on the secondary nanoparticles. Still further, there are provided a process for producing these nanoparticles, and a transdermal or transmucosal external preparation or injectable preparation in which these nanoparticles are contained.

    摘要翻译： 提供一种外用制剂或注射制剂，其具有使透皮或透粘膜能够吸收迄今为止未达到令人满意的脂溶性药物和水溶性药物的含量，并且含有高吸收性脂溶性/水溶性药物 ，注射剂，特别是针对持续释放和目标效应。 特别地，通过使含有脂溶性药物或脂溶性水溶性药物的一次纳米粒子与二价或三价金属盐起作用来提供含药纳米粒子（二次纳米粒子）。 此外，通过首先使含有脂溶性药物或脂溶性水溶性药物的一次纳米颗粒与二价或三价金属盐起作用，从而获得二次纳米粒子，然后使单价 至三价碱性盐作用于二次纳米颗粒。 此外，提供了制备这些纳米颗粒的方法，以及包含这些纳米颗粒的透皮或透粘膜外用制剂或可注射制剂。

    DERMAL REGENERATION ENHANCER
    4.
    发明申请
    DERMAL REGENERATION ENHANCER 审中-公开
    永久再生增强剂

    公开(公告)号：US20090017123A1

    公开(公告)日：2009-01-15

    申请号：US11912959

    申请日：2006-04-28

    申请人： Yoko Yamaguchi ,  Rie Igarashi

    发明人： Yoko Yamaguchi ,  Rie Igarashi

    IPC分类号： A61K9/14 ,  A61K31/07 ,  A61K31/11 ,  A61K31/70 ,  A61K38/44

    CPC分类号： A61K8/0295 ,  A61K8/86 ,  A61Q19/02 ,  A61Q19/08

    摘要： An object of the present invention is to provide a novel dermal regeneration enhancer. In accordance with the present invention, there is provided a dermal regeneration enhancer as a novel pharmaceutical use of lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, and the dermal regeneration enhancer of the present invention achieves an excellent suppressive effect to aging of the skin, generation of spots, etc.

    摘要翻译： 本发明的目的是提供一种新颖的皮肤再生增强剂。 根据本发明，提供了作为用作外用药用制剂和化妆品的基础材料的溶致液晶的新药用途的真皮再生增强剂，本发明的皮肤再生增强剂 对皮肤老化，斑点产生等产生极好的抑制作用

    THERAPEUTIC AGENT FOR LOCAL INFLAMMATION
    5.
    发明申请
    THERAPEUTIC AGENT FOR LOCAL INFLAMMATION 审中-公开
    局部炎症治疗剂

    公开(公告)号：US20110081410A1

    公开(公告)日：2011-04-07

    申请号：US11993209

    申请日：2006-06-23

    申请人： Rie Igarashi

    发明人： Rie Igarashi

    IPC分类号： A61K9/48 ,  A61K31/203 ,  A61K31/07 ,  A61P29/00 ,  A61P19/02

    CPC分类号： A61K9/0014 ,  A61K9/5115 ,  A61K31/07 ,  A61K31/203

    摘要： The agents of the present invention comprise, as a main ingredient, a polyvalent metal inorganic-salt nanocapsule which encapsulates a retinoid such as retinoic acid. The agents could penetrate into a joint when applied to the skin and induce hyaluronic acid production in a synovial membrane or chondrocyte. Moreover, application of the nanocapsule of the present invention to the skin for a certain period of time lowered the values of inflammatory cytokines and MMPs in the blood.

    摘要翻译： 作为主要成分，本发明的药剂含有视黄酸等视黄酸类的多价金属无机盐纳米胶囊。 当施用于皮肤并且在滑膜或软骨细胞中诱导透明质酸产生时，所述药剂可以渗透到关节中。 此外，本发明的纳米胶囊在皮肤上施用一定时间降低了血液中炎性细胞因子和MMP的值。

    TRANSDERMAL ABSORPTION ENHANCER
    7.
    发明申请
    TRANSDERMAL ABSORPTION ENHANCER 审中-公开
    超吸收增强剂

    公开(公告)号：US20090075860A1

    公开(公告)日：2009-03-19

    申请号：US11912964

    申请日：2006-04-28

    申请人： Yoko Yamaguchi ,  Rie Igarashi

    发明人： Yoko Yamaguchi ,  Rie Igarashi

    IPC分类号： A61K38/02 ,  A61K47/44 ,  A61K47/34 ,  A61K47/06 ,  A61K31/711

    CPC分类号： A61K31/23 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/1274 ,  A61K31/203 ,  A61K47/12 ,  A61K47/44

    摘要： An object of the present invention is to provide a transdermal absorption enhancer by which various active ingredients are transdermally absorbed. In accordance with a transdermal absorption enhancer of the present invention which effective ingredient is lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, transdermal absorption of a macromolecular substance and a water-soluble substance was able to be improved.

    摘要翻译： 本发明的目的是提供一种经皮吸收增强剂，通过其可以透皮吸收各种活性成分。 根据本发明的透皮吸收增强剂，其有效成分是已经用作外用药物制剂和化妆品的基础材料的溶致液晶，能够对大分子物质和水溶性物质进行经皮吸收 要改进

    Retinoic Acid-Containing Antidiabetic Agent
    8.
    发明申请
    Retinoic Acid-Containing Antidiabetic Agent 审中-公开
    含视黄酸的抗糖尿病药

    公开(公告)号：US20080274193A1

    公开(公告)日：2008-11-06

    申请号：US10586775

    申请日：2005-01-21

    申请人： Yoko Yamaguchi ,  Rie Igarashi

    发明人： Yoko Yamaguchi ,  Rie Igarashi

    IPC分类号： A61K31/203 ,  C07C57/03 ,  A61K9/14 ,  A61P3/10

    CPC分类号： A61K31/203

    摘要： The present invention aims to provide a novel agent for treating and/or preventing diabetes which agent can not only control a blood sugar level but also fundamentally treat a patient with type I diabetes suffering from destruction of β cells and a patient with type II diabetes suffering from dysfunction in insulin secretion. The present invention provides an agent for treating and/or preventing diabetes, the agent containing retinoic acid as an active ingredient. Retinoic acid incorporated as an active ingredient may be all-trans retinoic acid, an isomer thereof, a derivative thereof, a salt thereof or a prodrug thereof. Retinoic acid may be incorporated singly. Alternatively, composite particles of retinoic acid and an appropriate inorganic or organic substance are prepared, and the retinoic acid composite particles may be incorporated.

    摘要翻译： 本发明的目的在于提供一种用于治疗和/或预防糖尿病的新型药剂，其不仅可以控制血糖水平，而且可以从根本上治疗患有β细胞破坏的I型糖尿病患者和患有II型糖尿病的患者 从胰岛素分泌功能障碍。 本发明提供了用于治疗和/或预防糖尿病的药剂，其含有视黄酸作为活性成分。 作为活性成分掺入的视黄酸可以是全反式视黄酸，其异构体，其衍生物，其盐或其前药。 维甲酸可以单独加入。 或者，制备视黄酸和合适的无机或有机物质的复合颗粒，并且可以加入视黄酸复合颗粒。

    Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method
    9.
    发明申请
    Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method 审中-公开
    通过控制方法获得的用多价金属无机盐和纳米粒子涂覆的视黄酸纳米颗粒的粒度控制方法

    公开(公告)号：US20070014863A1

    公开(公告)日：2007-01-18

    申请号：US10595412

    申请日：2003-10-15

    申请人： Yoko Yamaguchi ,  Rie Igarashi ,  Yutaka Mizushima ,  Mitsuko Takenaga

    发明人： Yoko Yamaguchi ,  Rie Igarashi ,  Yutaka Mizushima ,  Mitsuko Takenaga

    IPC分类号： A61K9/14 ,  A61K31/203

    CPC分类号： A61K9/5115 ,  A61K9/1075 ,  A61K9/5089 ,  A61K9/5192 ,  A61K31/203 ,  A61K47/02

    摘要： Nanoparticles containing retinoic acid have reduced irritancy of retinoic acid and are suitable for subcutaneous or intravenous administration, as well as for use in sustained-release preparation. The high skin permeability of the nanoparticles makes them suitable for use in pharmaceutical or non-pharmaceutical external preparations or cosmetics intended for skin application. The present invention provides a method for adjusting the particle size of such nanoparticles and nanoparticles produced by such a method. Specifically, the method involves dispersing retinoic acid dissolved in a lower alcohol in an aqueous alkali solution; adding a nonionic surfactant to the dispersion to form a mixed micelle; adding to the micelle a halide or acetate of divalent metal along with a carbonate or phosphate of alkali metal so that the molar ratio of the former to the latter is 1:0 to 1:1.0, thereby depositing a coating of inorganic salt of polyvalent metal on the surface of the micelle; and adjusting the average particle size of the resulting nanoparticles to 5 to 300 nm. The inorganic salt of polyvalent metal may be calcium carbonate, zinc carbonate, or calcium phosphate.

    摘要翻译： 含视黄酸的纳米粒子具有降低视黄酸的刺激性，适用于皮下或静脉内给药以及用于持续释放制剂。 纳米颗粒的高皮肤渗透性使得它们适用于用于皮肤应用的药物或非药物外用制剂或化妆品。 本发明提供了一种调节由这种方法生产的纳米颗粒和纳米粒子的粒径的方法。 具体地说，该方法包括将溶解在低级醇中的视黄酸分散在碱性水溶液中; 向分散体中加入非离子表面活性剂以形成混合胶束; 向胶束中加入二价金属的卤化物或乙酸酯以及碱金属的碳酸盐或磷酸盐，使得前者与后者的摩尔比为1:0至1:1.0，由此沉积多价金属的无机盐的涂层 在胶束的表面上; 并将所得纳米粒子的平均粒径调整为5〜300nm。 多价金属的无机盐可以是碳酸钙，碳酸锌或磷酸钙。